Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).
Dong-Wan Kim
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Keunchil Park
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim (U); Clovis; Lilly; Roche
Research Funding - AstraZeneca
Ji-Youn Han
No relevant relationships to disclose
Jong-Seok Lee
No relevant relationships to disclose
In-Jin Jang
Research Funding - Hanmi
Hyo-Yeon Kim
No relevant relationships to disclose
Jeewoong Son
No relevant relationships to disclose
Joo-Hang Kim
Research Funding - Hanmi; Lilly; Pfizer; Roche